Clinical Cases in Pharmacology Clinical Cases  ·  Psychiatry IV  ·  Substance-Related Disorders  ·  Continuing MOUD After Relapse
Psychiatry IV, Case SubstanceRelated-0011 — Substance-Related Disorders

Continuing MOUD After a Relapse to Use While in Treatment

A patient stable on buprenorphine for over a year discloses, unprompted, a single use nine days ago. The question isn’t whether to punish it — it’s what an honest response to real risk looks like without discarding fourteen months of real progress.

Abbreviations, terms, and other agents mentioned in this case MOUD — medication for opioid use disorder  ·  OUD — opioid use disorder
Presentation

P.K. brought it up himself, before the test result was even back. He is thirty-four, and spends most Sunday afternoons restoring an old motorcycle in his neighbor's garage — a project he started shortly after beginning buprenorphine treatment fourteen months ago and has stuck with longer than almost anything else in his adult life. His neighbor, who taught him most of what he knows about engines, has become something close to a mentor, and P.K. credits the routine of showing up every Sunday as part of what has kept him steady through the harder stretches.

His opioid use disorder began with a prescription following a shoulder surgery six years ago and progressed to heroin, then fentanyl, before he started treatment. He has attended every scheduled appointment at his clinic without exception, held a steady job at a hardware store for the past year, and has no other significant medical history. His routine urine toxicology at this visit returned positive for fentanyl — unexpected, given his otherwise clean pattern over the past ten months. Asked directly, he admitted to using once, nine days ago, after an unusually difficult phone call with his estranged father reopened something he thought he'd worked through years earlier.

He says he felt immediate regret and did not use again despite having the opportunity to. He remains on his prescribed buprenorphine dose, has missed no doses, and told the team himself because, in his words, he'd rather they hear it from him than find out and wonder what else he might be hiding. He is visibly anxious, now, about how this particular conversation will go.

P.K. · 34 Single Positive Screen, Otherwise Adherent
History
OUD; buprenorphine maintenance × 14 months, clean toxicology × 10 months prior
This visit
Toxicology positive for fentanyl; single admitted use 9 days ago
Adherence otherwise
No missed appointments, no missed doses, stable employment
Trigger identified
Specific, named emotional precipitant; no repeat use since

A single positive screen after ten months clean

Addiction Psychiatrist Opening

Continue his buprenorphine without interruption, and don't frame this as a failure. He disclosed this himself, unprompted by the test result alone, after fourteen months of otherwise consistent engagement — stable job, no missed doses, no missed appointments. A "treatment failure" response to a single, honestly disclosed, non-repeated use doesn't just misread his actual trajectory, it actively discourages the honesty that let us know about it at all, in him and in every future patient who hears how this kind of disclosure gets handled.

Addiction Medicine Specialist Response

I agree we shouldn't discontinue his treatment or treat this punitively, but I want to name the real risk plainly: a positive fentanyl screen, even once, is a genuine safety event given how unpredictable current supply potency is. I don't think noting it and moving on is enough — I'd want a concrete, structured response, not just an observation for the chart.

His fourteen-month pattern matters, but it doesn't neutralize the actual lethality risk of that one exposure — the two facts sit alongside each other rather than one canceling the other out.

Primary Care Physician Final

I don't think these actually conflict. Continue his buprenorphine unchanged, and add a same-day counseling referral specifically addressing the trigger he named, plus a brief period of more frequent check-ins — not a higher level of care that would disrupt his job or housing, since nothing else in his pattern suggests that's warranted, but enough additional support that this specific vulnerability gets addressed rather than just documented.

Regimen selected
Buprenorphine-Naloxone (continued, unchanged)
Partial Opioid Agonist
Not interrupted or reduced in response to a single disclosed, non-repeated use.
Same-Day Counseling Referral
Care Coordination · Trigger-specific
Directly addresses the named emotional precipitant rather than treating the event as closed once documented.
Brief Increased Check-In Frequency
Monitoring · Time-limited, not escalation of level of care
A concrete response to the real overdose-risk concern without disrupting his stable job and housing.
Where this was left

Agreed: buprenorphine continued unchanged, same-day counseling referral made, and a four-week period of weekly rather than monthly check-ins before returning to his prior visit schedule if he remains stable.

Not agreed: what threshold of use should trigger a more structural response than this in future patients — a single use, a pattern of repeated use, or something else. The addiction medicine specialist wants a clearer standing threshold defined for the clinic rather than deciding case by case each time; the addiction psychiatrist is wary that any fixed threshold risks becoming a rule applied mechanically rather than a judgment made about the actual person in front of them.

Educational content only — a composite teaching case, not a real patient encounter or a substitute for clinical guidance. About These Cases →